Perspectives on oncology personalised healthcare: Malcolm Ranson


In the build-up to pharmaphorum's first round table video debate, due to be published at the end of September on oncology personalised healthcare, Paul Tunnah speaks with the first participant, expert researcher Professor Malcolm Ranson, to hear how it is already impacting on cancer treatment for patients.

(interview conducted July 2013)

This media accompanies the round table video debate 'Oncology shaping the future of personalised healthcare', sponsored by AstraZeneca.

Ahead of the round table video debate 'Oncology shaping the future of personalised medicine', pharmaphorum will be releasing individual video interviews with the four expert participants. Here, Paul Tunnah speaks with Professor Malcolm Ranson, an expert cancer researcher and clinician, to hear his views on how personalised healthcare is changing the way physicians view and treat cancer, plus the impact it is having on their patients.


0'25" – What does personalised healthcare mean to you?

0'56" – Does personalised medicine mean we need to reclassify cancer?

1'45" – How does personalised healthcare impact clinical specialisation?

2'36" – How well do current diagnostic processes support personalised healthcare?

3'20" – What is the main benefit of personalised healthcare for patients?

3'58" – What is holding personalised healthcare back?

4'57" – How do we ensure all cancer patients benefit from personalised healthcare?

Other links:

Oncology shaping the future of personalised healthcare media hub

Written transcript of this interview

Read about personalised healthcare on LabTalk – the AstraZeneca science blog


About the interviewee:

Malcolm Ranson is Professor of Medical Oncology and Pharmacology at the University of Manchester and has been an Honorary Consultant at the Christie Hospital since 1995. He leads a team of clinical researchers at the Christie Hospital conducting Phase I clinical trials focused on apoptosis, cell signalling and biomarker development. His clinical work is closely aligned with the translational biomarker work of Professor Caroline Dive and the Clinical and Experimental Pharmacology group based in the Paterson Institute. He instigated and led development of the Early Phase Trials Unit at the Christie Hospital in Manchester which opened in 2003 and was its Clinical Director for 10 years. The Oak Road Treatment Centre is one of the largest early phase clinical research units in Europe and draws upon a large patient population and is part of the Manchester Cancer Research Centre. Malcolm is the joint centre lead for the Manchester Experimental Cancer Medicine Centre, funded by Cancer Research UK and the Department of Health to support and develop translational cancer research locally and nationally.

For more information about his work please visit the following pages:

Professor Malcolm Ranson at the University of Manchester

The Christie Foundation Trust Clinical Trials Unit


17 September, 2013